Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Takuya TsujinoSatoshi TokushigeKazumasa KomuraWataru FukuokayaTakahiro AdachiYosuke HirasawaTakeshi HashimotoAtsuhiko YoshizawaMasanobu SarutaTakaya OhnoKeita NakamoriRyoichi MaenosonoKazuki NishimuraShogo YamazakiTaizo UchimotoTakafumi YanagisawaKeiichiro MoriNobuyoshi KosakaShunsuke TsuzukiKosuke IwataniShutaro YamamotoKiyoshi TakaharaTeruo InamotoTakahiro KimuraYoshio OhnoRyoichi ShirokiHaruhito AzumaPublished in: Cancer medicine (2023)
Our real-world survival analysis suggests that while AA plus prednisone may demonstrate comparable treatment efficacy to Enz in the context of nmCRPC, there may be an increased risk of non-cancer-caused death. Physicians should take into consideration this information when making treatment decisions for patients with nmCRPC.